Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.33 |
| ▸ | TPH1 | P17752 | 2/20 | 0.33 |
| ▸ | CIT | O14578 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | WNT3A | P56704 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4519177 | 0.92 | GPR142 (0.46) | GPR142CYP17A1TPH1CITCYP3A4 | |
| SCHEMBL4527459 | 0.89 | GPR142 (0.43) | GPR142CYP17A1TPH1 | |
| SCHEMBL4514376 | 0.89 | GPR142 (0.43) | GPR142CYP17A1TPH1 | |
| SCHEMBL4517312 | 0.89 | GPR142 (0.43) | GPR142CYP17A1CYP3A4 | |
| SCHEMBL4526794 | 0.88 | TPH1 (0.39) | GPR142CYP17A1PTPN1TPH1AAK1 | |
| SCHEMBL4516262 | 0.87 | MC4R (0.39) | GPR142CYP17A1 | |
| SCHEMBL4523323 | 0.86 | GPR142 (0.45) | GPR142CYP17A1TPH1MMP12MMP13 | |
| SCHEMBL4524956 | 0.82 | ROCK1 (0.50) | GPR142CYP17A1ABHD6CYP3A4 | |
| SCHEMBL4533235 | 0.81 | CYP17A1 (0.39) | GPR142CYP17A1ACACBABHD6AAK1 | |
| SCHEMBL4525695 | 0.80 | P2RX7 (0.38) | CYP17A1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211919-B2 | Amide derivatives as rock inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105231-A1 | AMIDE DERIVATIVES AS ROCK INHIBITORS | ROCK1, ROCK2, RHOA | GPR142 3166/4885CYP17A1 3015/4885ACACB 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.